TSHA · Taysha Gene Therapies, Inc. · Financials
$4.74
-0.13 (-2.67%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$1.52B
Shares
325.83M
Volume · Oct 1
3.85M
Avg daily vol (3M)
3.16M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$9.77M
+17.3%
FY2025
Net Income
-$109M
-22.1%
FY2025
Operating Margin
-1130.65%
-33.1pp
FY2025
Diluted EPS
-$0.34
+5.6%
FY2025
Operating Cash Flow
-$93.09M
-14.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $5.49M | $9.77M | $8.33M | $15.45M | $2.5M | — | — | |
| $123.14M | $86.4M | $66M | $56.78M | $91.17M | $131.94M | $31.89M | |
| $38.94M | $33.87M | $28.95M | $30.05M | $37.36M | $41.32M | $11.11M | |
| $158.64M | $120.27M | $99.79M | $87.89M | $164.95M | $173.27M | $43M | |
| -$153.16M | -$110.5M | -$91.46M | -$72.44M | -$162.45M | -$173.27M | -$43M | |
| — | -1130.65% | -1097.55% | -468.83% | -6492.69% | — | — | |
| $42K | $63K | $102K | $5M | $3.8M | $1.43M | $28K | |
| $10.95M | $9.22M | $6.94M | $3.57M | — | — | — | |
| $3.53M | $1.5M | $2.16M | -$39.13M | -$3.57M | -$1.26M | -$17.01M | |
| $0 | $0 | $0 | $0 | $0 | — | $0 | |
| -$149.63M | -$109M | -$89.3M | -$111.57M | -$166.01M | -$174.52M | -$60.01M | |
| — | -1115.27% | -1071.62% | -722.06% | -6635.25% | — | — | |
| USD/shares | -$0.42 | -$0.34 | -$0.36 | -$0.96 | -$3.78 | -$4.64 | — |
| USD/shares | -$0.42 | -$0.34 | -$0.36 | -$0.96 | -$3.78 | -$4.64 | — |
| shares | — | 319.71M | 250.13M | 116.12M | 43.95M | 37.65M | 17.67M |
| shares | — | 319.71M | 250.13M | 116.12M | 43.95M | 37.65M | 17.67M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 7.46×
EV/EBIT
—
Peer median 13.48×
P/E (TTM)
—
Peer median 18.23×
Peer medians compare against the 264 similar-size Biotechnology companies (of 532 listed).